Neurocrine Biosciences Inc (NBIX)
Debt-to-assets ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | 169,500 | 0 | 0 | 169,000 | 377,700 | 335,100 | 330,700 | 326,300 | 322,000 | 317,900 | 425,000 | 419,500 | 414,100 |
| Total assets | US$ in thousands | 3,718,700 | 3,535,000 | 3,305,000 | 3,472,400 | 3,251,400 | 2,848,200 | 2,613,100 | 2,359,800 | 2,368,700 | 2,143,400 | 2,005,700 | 2,144,500 | 2,072,500 | 2,017,300 | 1,956,400 | 1,846,400 | 1,734,700 | 1,502,600 | 1,515,600 | 1,361,900 |
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.08 | 0.18 | 0.16 | 0.16 | 0.17 | 0.17 | 0.18 | 0.28 | 0.28 | 0.30 |
December 31, 2024 calculation
Debt-to-assets ratio = Long-term debt ÷ Total assets
= $—K ÷ $3,718,700K
= 0.00
The debt-to-assets ratio of Neurocrine Biosciences Inc has shown a consistent downward trend over the past few years, indicating a healthier financial position in terms of leverage. As of December 31, 2024, the company's debt-to-assets ratio stands at 0.00, suggesting that the company has no debt relative to its total assets, which is a positive sign for investors and creditors. This trend indicates that the company has been able to reduce its debt obligations or increase its asset base over time. A lower debt-to-assets ratio generally implies lower financial risk and greater financial stability for the company. It is important for investors to monitor this ratio to assess the company's ability to meet its debt obligations and to evaluate its overall financial health.
Peer comparison
Dec 31, 2024